<?xml version="1.0" encoding="utf-8" standalone="no"?>
<billStatus>
  <version>3.0.0</version>
  <bill>
    <number>415</number>
    <updateDate>2022-12-31T08:47:59Z</updateDate>
    <updateDateIncludingText>2022-12-31T08:47:59Z</updateDateIncludingText>
    <originChamber>Senate</originChamber>
    <type>S</type>
    <introducedDate>2021-02-24</introducedDate>
    <congress>117</congress>
    <committees>
      <item>
        <systemCode>sshr00</systemCode>
        <name>Health, Education, Labor, and Pensions Committee</name>
        <chamber>Senate</chamber>
        <type>Standing</type>
        <activities>
          <item>
            <name>Discharged from</name>
            <date>2021-03-10T15:25:20Z</date>
          </item>
          <item>
            <name>Referred to</name>
            <date>2021-02-24T20:18:30Z</date>
          </item>
        </activities>
      </item>
    </committees>
    <actions>
      <item>
        <actionDate>2021-04-23</actionDate>
        <text>Became Public Law No: 117-9.</text>
        <type>President</type>
        <actionCode>E40000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2021-04-23</actionDate>
        <text>Became Public Law No: 117-9.</text>
        <type>BecameLaw</type>
        <actionCode>36000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2021-04-23</actionDate>
        <text>Signed by President.</text>
        <type>President</type>
        <actionCode>E30000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2021-04-23</actionDate>
        <text>Signed by President.</text>
        <type>BecameLaw</type>
        <actionCode>36000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2021-04-20</actionDate>
        <text>Presented to President.</text>
        <type>Floor</type>
        <actionCode>E20000</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2021-04-20</actionDate>
        <text>Presented to President.</text>
        <type>President</type>
        <actionCode>28000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2021-04-14</actionDate>
        <actionTime>13:23:54</actionTime>
        <text>Motion to reconsider laid on the table Agreed to without objection.</text>
        <type>Floor</type>
        <actionCode>H38310</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2021-04-14</actionDate>
        <actionTime>13:23:47</actionTime>
        <text>On motion to suspend the rules and pass the bill Agreed to by voice vote. (text: CR H1755)</text>
        <type>Floor</type>
        <actionCode>H37300</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2021-04-14</actionDate>
        <actionTime>13:23:47</actionTime>
        <text>Passed/agreed to in House: On motion to suspend the rules and pass the bill Agreed to by voice vote.(text: CR H1755)</text>
        <type>Floor</type>
        <actionCode>8000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2021-04-14</actionDate>
        <actionTime>13:17:55</actionTime>
        <text>DEBATE - The House proceeded with forty minutes of debate on S. 415.</text>
        <type>Floor</type>
        <actionCode>H8D000</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2021-04-14</actionDate>
        <actionTime>13:17:51</actionTime>
        <text>Considered under suspension of the rules. (consideration: CR H1755-1756)</text>
        <type>Floor</type>
        <actionCode>H30000</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2021-04-14</actionDate>
        <actionTime>13:17:27</actionTime>
        <text>Mr. Pallone moved to suspend the rules and pass the bill.</text>
        <type>Floor</type>
        <actionCode>H30300</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2021-03-12</actionDate>
        <actionTime>10:58:11</actionTime>
        <text>Held at the desk.</text>
        <type>Floor</type>
        <actionCode>H15000</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2021-03-12</actionDate>
        <actionTime>10:37:57</actionTime>
        <text>Received in the House.</text>
        <type>Floor</type>
        <actionCode>H14000</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2021-03-11</actionDate>
        <sourceSystem>
          <name>Senate</name>
        </sourceSystem>
        <text>Message on Senate action sent to the House.</text>
        <type>Floor</type>
      </item>
      <item>
        <actionDate>2021-03-10</actionDate>
        <sourceSystem>
          <name>Senate</name>
        </sourceSystem>
        <text>Passed Senate without amendment by Unanimous Consent. (text: CR S1435)</text>
        <type>Floor</type>
      </item>
      <item>
        <actionDate>2021-03-10</actionDate>
        <text>Passed/agreed to in Senate: Passed Senate without amendment by Unanimous Consent.(text: CR S1435)</text>
        <type>Floor</type>
        <actionCode>17000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2021-03-10</actionDate>
        <committees>
          <item>
            <systemCode>sshr00</systemCode>
            <name>Health, Education, Labor, and Pensions Committee</name>
          </item>
        </committees>
        <sourceSystem>
          <name>Senate</name>
        </sourceSystem>
        <text>Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent. (consideration: CR S1435)</text>
        <type>Discharge</type>
      </item>
      <item>
        <actionDate>2021-03-10</actionDate>
        <text>Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent.(consideration: CR S1435)</text>
        <type>Committee</type>
        <actionCode>14500</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
        <committees>
          <item>
            <systemCode>sshr00</systemCode>
            <name>Health, Education, Labor, and Pensions Committee</name>
          </item>
        </committees>
      </item>
      <item>
        <actionDate>2021-02-24</actionDate>
        <committees>
          <item>
            <systemCode>sshr00</systemCode>
            <name>Health, Education, Labor, and Pensions Committee</name>
          </item>
        </committees>
        <sourceSystem>
          <name>Senate</name>
        </sourceSystem>
        <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
        <type>IntroReferral</type>
      </item>
      <item>
        <actionDate>2021-02-24</actionDate>
        <text>Introduced in Senate</text>
        <type>IntroReferral</type>
        <actionCode>10000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
    </actions>
    <sponsors>
      <item>
        <bioguideId>C001075</bioguideId>
        <fullName>Sen. Cassidy, Bill [R-LA]</fullName>
        <firstName>Bill</firstName>
        <lastName>Cassidy</lastName>
        <party>R</party>
        <state>LA</state>
        <identifiers>
          <bioguideId>C001075</bioguideId>
        </identifiers>
        <isByRequest>N</isByRequest>
      </item>
    </sponsors>
    <cosponsors>
      <item>
        <bioguideId>S001203</bioguideId>
        <fullName>Sen. Smith, Tina [D-MN]</fullName>
        <firstName>Tina</firstName>
        <lastName>Smith</lastName>
        <party>D</party>
        <state>MN</state>
        <identifiers>
          <bioguideId>S001203</bioguideId>
        </identifiers>
        <sponsorshipDate>2021-02-24</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>M001198</bioguideId>
        <fullName>Sen. Marshall, Roger [R-KS]</fullName>
        <firstName>Roger</firstName>
        <lastName>Marshall</lastName>
        <party>R</party>
        <state>KS</state>
        <identifiers>
          <bioguideId>M001198</bioguideId>
        </identifiers>
        <sponsorshipDate>2021-02-24</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
    </cosponsors>
    <laws>
      <item>
        <type>Public Law</type>
        <number>117-9</number>
      </item>
    </laws>
    <policyArea>
      <name>Health</name>
    </policyArea>
    <subjects>
      <legislativeSubjects>
        <item>
          <name>Administrative law and regulatory procedures</name>
        </item>
        <item>
          <name>Chemistry</name>
        </item>
        <item>
          <name>Department of Health and Human Services</name>
        </item>
        <item>
          <name>Drug safety, medical device, and laboratory regulation</name>
        </item>
      </legislativeSubjects>
      <policyArea>
        <name>Health</name>
      </policyArea>
    </subjects>
    <summaries>
      <summary>
        <versionCode>00</versionCode>
        <actionDate>2021-02-24</actionDate>
        <actionDesc>Introduced in Senate</actionDesc>
        <updateDate>2021-05-04T19:23:22Z</updateDate>
        <text>
          <![CDATA[ <p>This bill provides statutory authority for the existing Food and Drug Administration (FDA) practice of defining <i>active ingredient </i>more narrowly as <i>active moiety</i> in certain situations, such as when determining whether a new drug is entitled to a market exclusivity period or providing priority review of drugs for treating rare pediatric diseases. <br /></p> <p>Generally, the FDA defines <i>active moiety</i> as the core molecule or ion in a drug responsible for the relevant physiological or pharmacological action. By contrast, the FDA defines an <i>active ingredient </i>as a component in a drug that is intended to furnish pharmacological activity or other direct effect. The FDA's existing practice of interpreting <i>active ingredient</i> as <i>active moiety</i> in certain situations, as statutorily authorized by this bill, tends to exclude some drugs from market exclusivity.</p> <p>The bill replaces references to <i>active ingredient</i> with <i>active moiety</i> in various statutes authorizing FDA activities.</p>]]>
        </text>
      </summary>
      <summary>
        <versionCode>55</versionCode>
        <actionDate>2021-03-10</actionDate>
        <actionDesc>Passed Senate</actionDesc>
        <updateDate>2021-05-04T20:59:03Z</updateDate>
        <text>
          <![CDATA[ <p>This bill provides statutory authority for the existing Food and Drug Administration (FDA) practice of defining <i>active ingredient </i>more narrowly as <i>active moiety</i> in certain situations, such as when determining whether a new drug is entitled to a market exclusivity period or providing priority review of drugs for treating rare pediatric diseases. <br /> </p> <p>Generally, the FDA defines <i>active moiety</i> as the core molecule or ion in a drug responsible for the relevant physiological or pharmacological action. By contrast, the FDA defines an <i>active ingredient </i>as a component in a drug that is intended to furnish pharmacological activity or other direct effect. The FDA's existing practice of interpreting <i>active ingredient</i> as <i>active moiety</i> in certain situations, as statutorily authorized by this bill, tends to exclude some drugs from market exclusivity.</p> <p>The bill replaces references to <i>active ingredient</i> with <i>active moiety</i> in various statutes authorizing FDA activities.</p>]]>
        </text>
      </summary>
      <summary>
        <versionCode>53</versionCode>
        <actionDate>2021-04-14</actionDate>
        <actionDesc>Passed House</actionDesc>
        <updateDate>2021-05-04T20:59:52Z</updateDate>
        <text>
          <![CDATA[ <p>This bill provides statutory authority for the existing Food and Drug Administration (FDA) practice of defining <i>active ingredient </i>more narrowly as <i>active moiety</i> in certain situations, such as when determining whether a new drug is entitled to a market exclusivity period or providing priority review of drugs for treating rare pediatric diseases. </p> <p>Generally, the FDA defines <i>active moiety</i> as the core molecule or ion in a drug responsible for the relevant physiological or pharmacological action. By contrast, the FDA defines an <i>active ingredient </i>as a component in a drug that is intended to furnish pharmacological activity or other direct effect. The FDA's existing practice of interpreting <i>active ingredient</i> as <i>active moiety</i> in certain situations, as statutorily authorized by this bill, tends to exclude some drugs from market exclusivity.</p> <p>The bill replaces references to <i>active ingredient</i> with <i>active moiety</i> in various statutes authorizing FDA activities.</p>]]>
        </text>
      </summary>
      <summary>
        <versionCode>49</versionCode>
        <actionDate>2021-04-23</actionDate>
        <actionDesc>Public Law</actionDesc>
        <updateDate>2021-05-04T20:59:29Z</updateDate>
        <text>
          <![CDATA[ <p>This bill provides statutory authority for the existing Food and Drug Administration (FDA) practice of defining <i>active ingredient </i>more narrowly as <i>active moiety</i> in certain situations, such as when determining whether a new drug is entitled to a market exclusivity period or providing priority review of drugs for treating rare pediatric diseases. </p> <p>Generally, the FDA defines <i>active moiety</i> as the core molecule or ion in a drug responsible for the relevant physiological or pharmacological action. By contrast, the FDA defines an <i>active ingredient </i>as a component in a drug that is intended to furnish pharmacological activity or other direct effect. The FDA's existing practice of interpreting <i>active ingredient</i> as <i>active moiety</i> in certain situations, as statutorily authorized by this bill, tends to exclude some drugs from market exclusivity.</p> <p>The bill replaces references to <i>active ingredient</i> with <i>active moiety</i> in various statutes authorizing FDA activities.</p>]]>
        </text>
      </summary>
    </summaries>
    <title>A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the scope of new chemical exclusivity.</title>
    <titles>
      <item>
        <titleType>Display Title</titleType>
        <title>A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the scope of new chemical exclusivity.</title>
      </item>
      <item>
        <titleType>Official Title as Introduced</titleType>
        <title>A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the scope of new chemical exclusivity.</title>
      </item>
    </titles>
    <textVersions>
      <item>
        <type>Enrolled Bill</type>
        <date/>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-117s415enr/xml/BILLS-117s415enr.xml</url>
          </item>
        </formats>
      </item>
      <item>
        <type>Engrossed in Senate</type>
        <date>2021-03-10T05:00:00Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-117s415es/xml/BILLS-117s415es.xml</url>
          </item>
        </formats>
      </item>
      <item>
        <type>Introduced in Senate</type>
        <date>2021-02-24T05:00:00Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-117s415is/xml/BILLS-117s415is.xml</url>
          </item>
        </formats>
      </item>
      <item>
        <date>2021-04-24T03:59:59Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/PLAW-117publ9/xml/PLAW-117publ9.xml</url>
          </item>
        </formats>
        <type>Public Law</type>
      </item>
    </textVersions>
    <latestAction>
      <actionDate>2021-04-23</actionDate>
      <text>Became Public Law No: 117-9.</text>
    </latestAction>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>
